Clinical Trial Search

Primary: Dose Limiting Toxicity (DLT) Rate by the NCI Common Toxicity Criteria (CTCAE) v2.0 and the Method of Przepiorka et al (Protocol Appendix I) — 0; 0; 0; 0 proportion of…

Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…

Primary: Number of Recipients Who Developed Grades I-IV Acute Graft Versus Host Disease (GVHD) Following a Combination of Cyclosporine and a Mini-dose Methotrexate Regimen for…

Primary: Number of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma — 2; 3; 2; 3 Participants

Primary: Complete Remission Rate — 8; 6 Participants

Primary: Number of Participants With Absolute Neutrophil Count >= 500/Mcl for 3 Consecutive Measurements on Different Days and Platelet Count > 20,000/mm^3 With no Platelet…

Primary: Number of Patients Who Obtain Partial Response/Complete Remission — 1; 5 Participants

Primary: Probability of Event-free Survival (EFS) — 91.7; 71.4; 100; 86.96 percentage of event-free patients

Primary: Relapse-free Complete Clinical Response — 54 Months

Primary: 68Ga-DOTANOC Uptake in Lymphomas With PET/CT — 3.1 Standardized Uptake Value

Primary: Response Rate — 0; 0; 1; 1 Participants

Primary: Number of Participants With Hematological Response After Three Months of Alemtuzumab — 15 Participants

Primary: Progression-Free Survival (PFS) — 73 percentage of participants

Primary: Composite Success Rate — 100; 75; 84 Percentage of participants

Primary: Concordance of Blue Dye and Lymphoseek — 1.0000 Proportion of Lymph Nodes

Primary: Survival at 1 Year After Transplantation — 10; 6 participants

Primary: Complete Remission — 10 participants

Primary: Proportion of Patients With CNS Involvement by B-cell NHL, Relapsed PCNSL, or Relapsed PIOL Who Are Alive and Progression-free at One Year — 28 Participants

Primary: Summary of Adverse Events (AEs) — 9; 13; 7; 12 participants

Primary: Participant's Response According to Physician's Global Assessment of Clinical Condition (PGA) — 19; 6; 0; 0 participants

Primary: Day 100 TRM — 4 Participants

Primary: Overall Response Rate (ORR) — 53.45; 51.85; 57.14; 50.00 percentage of participants

Primary: Percentage of Patients Assigned to Arm Latent Membrane Protein-specific T-cells (LMP-TC) With Successful LMP-specific T Cell Product Match, Were Treated Within Two Weeks…

Primary: 3-year Overall Survival Rate of Patients With Relapsed ALL — 94.4; 55.5; 72.63 percentage of participants — p=0.035

Primary: 1 Year Progression Free Survival (PFS) — 58 Percentage of participants

Primary: Transplant Related Mortality Rate — 1; 6 Participants

Primary: Efficacy of Nonmyeloablative Preparative Regimen — 4 Participants

Primary: Proportion of Patients From Whom a Total Number of CD34+ Cells ≥5.0 x 10^6 Cells/kg Was Collected Within the First 4 Leukapheresis Sessions — 0.50000; 0.9167; 0.9167…

Primary: Overall Survival at 1 Year — 90 percentage of participants

Primary: Cellular Immune Response — 4 participants